Effect of hyperthermia and chemotherapeutic agents on TRAIL-induced cell death in human colon cancer cells

Journal of Cellular Biochemistry

Volumn 103, Issue 1, 2008, Pages 98-109

  Yoo, Jinsang ^a   Lee, Yong J ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Caspase 3; Caspase 8; Caspase 9; Chemotherapeutic agents; Colon cancer; Hyperthermia; Isolated hepatic perfusion (IHP); Melphalan; Oxaliplatin; TRAIL

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 8; CASPASE 9; CYTOCHROME C; MELPHALAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; OXALIPLATIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL DEATH; CLONOGENIC ASSAY; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYPERTHERMIC THERAPY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CELL DEATH; CELL LINE, TUMOR; COLONIC NEOPLASMS; CYTOCHROMES C; HUMANS; MELPHALAN; MITOCHONDRIA; ORGANOPLATINUM COMPOUNDS; POLY(ADP-RIBOSE) POLYMERASES; TEMPERATURE; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 38149076296     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21389     Document Type: Article

References (37)

1. Alexander HR Jr, Bartlett DL, Libutti SK. 2000. Current status of isolated hepatic perfusion with or without tumor necrosis factor for the treatment of unresectable cancers confined to liver. Oncologist 5(5):416-424.
2. Alexander HR, Libutti SK, Bartlett DL, Puhlmann M, Fraker DL, Bachenheimer LC. 2000. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res 6(8):3062-3070.
3. Ashkenazi A, Dixit VM. 1999. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 11:255-260.
4. Ausman RK. 1961. Development of a technic for isolated perfusion of the liver. N Y State J Med. 1(61):3993-3997.
5. Boyle P, Langman JS. 2000. ABC of colorectal cancer. BMJ 321:805-808.
6. Chinnaiyan AM, Prasad U, Shankar S, Hamstra DA, Shanaiah M, Chenevert TL, Ross BD, Rehemtulla A. 2000. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Nat Acad Sci (USA) 97:1754-1759.
7. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. 2000. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18(16):2938-2947.
8. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG. 1997. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 7:813-820.
9. Degli-Esposti MA, Smolak PJ, Walczak H, Waugh J, Huang CP, DuBose RF, Goodwin RG, Smith CA. 1997. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 186:1165-1170.
10. Dewey WC, Sapareto SA, Betten DA. 1978. Hyperthermic radiosensitization of synchronous Chinese hamster cells: Relationship between lethality and chromosomal aberrations. Radiat Res 76:48-59.
11. Finlay IG, McArdle CS. 1986. Occult hepatic metastases in colorectal carcinoma. Br J Surg 73(9):732-735.
12. Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ. 1998. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 161:2833-2840.
13. Haas GP, Klugo RC, Hetzel FW, Barton EE, Cerny JC. 1984. The synergistic effect of hyperthermia and chemotherapy on murine transitional cell carcinoma. J Urol 132:828-833.
14. Herman TS, Sweets CC, White DM, Gerner EW. 1982. Effect of heating on lethality due to hyperthermia and selected chemotherapeutic drugs. J Natl Cancer Inst 68:487-491.
15. Holahan EV, Highfield DP, Holahan PK, Dewey WC. 1984. Hyperthermic killing and hyperthermic radiosensitization in Chinese hamster ovary cells: Effects of pH and thermal tolerance. Radiat Res 97:108-131.
16. Kampinga HH, Dikomey E. 2001. Hyperthermic radiosensitization: Mode of action and clinical relevance. Int J Radiat Biol 77:399-408.
17. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S. 1999. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 59:734-741.
18. Klostergaard J, Leroux E, Siddik ZH, Khodadadian M, Tomasovic SP. 1992. Enhanced sensitivity of human colon tumor cell lines in vitro in response to thermochemoimmunotherapy. Cancer Res 52:5271-5277.
19. Ko SH, Ueno T, Yoshimoto Y, Yoo JS, Abdel-Wahab OI, Abdel-Wahab Z, Chu E, Pruitt SK, Friedman HS, Dewhirst MW, Tyler DS. 2006. Optimizing a novel regional chemotherapeutic agent against melanoma: Hyperthermia-induced enhancement of temozolomide cytotoxicity. Clin Cancer Res 12:289-297.
20. Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227(5259):680-685.
21. Lee YJ, Hou Z, Curetty L, Cho JM, Corry PM. 1993. Synergistic effects of cytokine and hyperthermia on cytotoxicity in HT-29 cells are not mediated by alteration of induced protein levels. J Cell Physiol 155:27-35.
22. Marsters SA, Sheridan JP, Pitti RM, Brush J, Goddard A, Ashkenazi A. 1997. Identification of a ligand for the death-domain-containing receptor Apo3. Curr Biol 7:1003-1006.
23. Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK, Huang HJ. 2000. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res 60:847-853.
24. Noter SL, Rothbarth J, Pijl ME, Keunen JE, Hartgrink HH, Tijl FG, Kuppen PJ, van de Velde CJ, Tollenaar RA. 2004. Isolated hepatic perfusion with high-dose melphalan for the treatment of uveal melanoma metastases confined to the liver. Melanoma Res 14(1):67-72.
25. Nyormoi O, Mills L, Bar-Eli M. 2003. An MMP-2/MMP-9 inhibitor, 5a, enhances apoptosis induced by ligands of the TNF receptor superfamily in cancer cells. Cell Death Differ 10:558-569.
26. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. 1997. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277:815-818.
27. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM. 1997. The receptor for the cytotoxic ligand TRAIL. Science 276:111-113.
28. Park SY, Billiar TR, Seol DW. 2002. IFN-gamma inhibition of TRAIL-induced IAP-2 upregulation, a possible mechanism of IFN-gamma-enhanced TRAIL-induced apoptosis. Biochem Biophys Res Commun 291:233-236.
29. Ridge JA, Bading JR, Gelbard AS, Benua RS, Daly JM. 1987. Perfusion of colorectal hepatic metastases. Relative distribution of flow from the hepatic artery and portal vein. Cancer 1; 59(9):1547-1553.
30. Ridge JA, Sigurdson ER, Daly JM. 1987. Distribution of fiuorodeoxyuridine uptake in the liver and colorectal hepatic metastases of human beings after arterial infusion. Surg Gynecol Obstet 164(4):319-323.
31. Ruers T, Bleichrodt RP. 2002. Treatment of liver metastases, an update on the possibilities and results. Eur J Cancer 38(7):1023-1033.
32. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A. 1997. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277:818-821.
33. Srinivasan JM, Fajardo LF, Hahn GM. 1990. Mechanism of antitumor activity of tumor necrosis factor alpha with hyperthermia in a tumor necrosis factor alpha-resistant tumor. J Natl Cancer Inst 82:1904-1910.
34. Vahrmeijer AL, van Dierendonck JH, Keizer HJ, Beijnen JH, Tollenaar RA, Pijl ME, Marinelli A, Kuppen PJ, van Bockel JH, Mulder GJ, van de Velde CJ. 2000. Increased local cytostatic drug exposure by isolated hepatic perfusion: A phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver. Br J Cancer 82(9):1539-1546.
35. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA, Goodwin RG, Rauch CT. 1997. TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL. EMBO J 16:5386-5397.
36. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JCL, Lynch DH. 1999. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5:157-163.
37. Yoo J, Lee YJ. 2007. Effect of hyperthermia on TRAIL-induced apoptotic death in human colon cancer cells: Development of a novel strategy for regional therapy. J Cell Biochem Jan 9; [Epub ahead of print].